JNJ vs ABBV: Johnson & Johnson vs AbbVie Inc.
Side-by-side snapshot of two Healthcare companies — key metrics from our latest data. Reference only, not investment advice.
| Metric | JNJ | ABBV |
|---|---|---|
| Company | Johnson & Johnson | AbbVie Inc. |
| Price | $275.23 | $256.46 |
| Market Cap | $663.28B | $453.19B |
| P/E Ratio | 31.97 | 72.45 |
| EPS | $8.61 | $3.54 |
| Dividend Yield | 1.95% | 2.70% |
| 52-Week High | $281.07 | $267.47 |
| 52-Week Low | $173.33 | $190.75 |
| Beta | 0.23 | 0.28 |
| Return on Equity (ROE) | 25.74% | — |
| Debt-to-Equity | 57.71% | — |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYQ | NYQ |
| Employees | 138,200 | 57,000 |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Philip Fisher's growth-investing classic on evaluating management and moats.
Check Price →A desk whiteboard for tracking tickers, levels and ideas at a glance.
Check Price →Roger Lowenstein's definitive biography of the world's most famous investor.
Check Price →Johnson & Johnson and AbbVie Inc. both operate in the Healthcare sector. JNJ has a market cap of $663.28B versus ABBV's $453.19B. On valuation, JNJ carries a trailing P/E of 31.97 against 72.45 for ABBV. In terms of earnings, JNJ posts EPS of $8.61 versus ABBV's $3.54. For price range, JNJ has traded between $173.33 and $281.07 over the past 52 weeks, and ABBV between $190.75 and $267.47. On income, JNJ yields 1.95% versus ABBV's 2.70%. On volatility, ABBV carries the higher beta (JNJ 0.23 vs ABBV 0.28), meaning it has historically moved more sharply than the market. How these figures compare depends on each company's growth profile, margins and competitive position — this snapshot is a starting point for research, not a recommendation.
Comparing two companies becomes much more powerful once you can read their financials directly — financial statement analysis guides are a practical next step. Many investors track comparisons like this in a dedicated stock research journal.
Figures are from our latest data snapshot and may not reflect current market prices. See the full profiles: Johnson & Johnson and AbbVie Inc.. This is not financial advice.
Recommended Reading
Philip Fisher's growth-investing classic on evaluating management and moats.
Check Price →Tidy statements, reports and research with a simple desk filing organizer.
Check Price →Robert Kiyosaki's bestseller on assets, liabilities and financial literacy.
Check Price →